|
You are subscribed to Oncology (Cancer) / Hematologic Malignancies. This information has recently been updated, and is now available.
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
|
This email was sent to Esdek@podam.pl using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·
10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA |
 |
|
|
